Sharing his thoughts on the European funding landscape, the importance of software, and sustainable investments, INKEF Capital’s Thijs Cohen Tervaert talks to In Vivo about his investment priorities.

Medtech Insight spoke to the manufacturers of the smallest commercially available insulin pump to learn more about how it works, the market factors impacting it, and how scaling up a business can throw up unexpected challenges.

With an average return of 33.2% in 2017, the number of biopharma IPOs that launched last year rose to 42 after falling to 30 in 2016 compared with 62 in 2015. Following a rough fourth quarter for biopharma stocks, will the IPO momentum continue in 2018?

The UK biotech plans to move its early clinical-stage anticancers, designed to improve the efficacy and tolerability of established agents, through its R&D pipeline with the proceeds of its recent US IPO.